Arcutis Biotherapeutics reported Q2 2026 net product revenue of $129.9M, up 59% YoY and 23% sequentially, driven by rising demand for its ZORYVE topical treatments across approved dermatology indications. The strong growth trajectory suggests improving commercial momentum heading into upcoming quarters.
Arcutis Biotherapeutics reported Q2 2026 net product revenue of $129.9M, up 59% YoY and 23% sequentially, driven by rising demand for its ZORYVE topical treatments across approved dermatology indications. The strong growth trajectory suggests improving commercial momentum heading into upcoming quarters.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
Ticker Sentiment
